Phase I study of DFP-11207, a novel oral 5-FU with enhanced PK and improved tolerability, in patients with solid tumors.

Authors

null

Jaffer A. Ajani

The University of Texas MD Anderson Cancer Center, Houston, TX

Jaffer A. Ajani , Milind M. Javle , Cathy Eng , David R. Fogelman , Barry Douglas Anderson , Chun Zhang , Kenzo Iizuka

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics and Tumor Biology (Nonimmuno)

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Chemotherapy and Antibody-Drug Conjugates

Clinical Trial Registration Number

NCT02171221

Citation

J Clin Oncol 37, 2019 (suppl; abstr 3034)

DOI

10.1200/JCO.2019.37.15_suppl.3034

Abstract #

3034

Poster Bd #

26

Abstract Disclosures

Similar Posters

First Author: Nagla Fawzy Abdel Karim

First Author: Edward Samuel James

First Author: Edward Samuel James